1. Do you think there should be universal regulation for stem cell therapy provision that every country should follow?
2. Should every country adopt the same regulations?
3. The freedom of choice to medical treatment is often seen as an important aim by patient groups. Is this freedom currently curtailed?
4. What kinds of space should there be for innovative stem cell therapies?
Insoo Hyun, Case Western Reserve University School of Medicine, USA
Policy Panellists, listed alphabetically (same questions to all):
1. What kinds of stem cell therapy do you find unacceptable?
2. What kind of space do researchers need to develop innovative therapies?
3. What would you say to patients who say they cannot wait 5 or 10 years for certain stem cell therapies to be formally approved?
Paulo Bianco, University of Roma ‘La Sapienza’, Italy
Willem Fibbe, Leiden University Medical Centre, Netherlands
Hongyun Huang, Centre of Neurorestoratology, Beijing Rehabilitation Hospital of Capital Medical University, China
Kamthorn Pruksananonda, Chulalongkorn University, Bangkok Thailand
Alok Sharma, NeuroGen Brain and Spine Institute, Mumbai India
Geeta Shroff, Nutech Mediworld, New Dehli India
Parallel panel session films: